Biotech News

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MacroGenics (MGNX)MacroGenics2026-05-13 20:01 ESTEarnings

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and development Manufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5 million in combined proceeds ADC pipeline remains on track for multiple data

Open original release

Related news

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

GERNGeron2026-05-06 11:00 EST

Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights

COGTCogent Biosciences2026-05-05 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

LEGNLegend Biotech Corporation2026-05-12 11:00 EST

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

View all latest news

MacroGenics

MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.

Recent company news

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-05-04 11:30 EST

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MGNXMacroGenics2026-04-08 20:30 EST

FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study

Stock data

Close: 4.00 USD
Market cap: 257.43M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States